Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 8, 2006, Pages 933-944

  Azzaro, Albert J ^a   VanDenBerg, Chad M ^a,c   Blob, Lawrence F ^a   Kemper, Eva M ^a   Sharoky, Melvin ^a   Oren, Dan A ^b   Campbell, Bryan J ^b  

^a Somerset Pharmaceuticals   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c MERCER UNIVERSITY   (United States)

Author keywords

Depression; Monoamine oxidase inhibitor; Selegiline; Transdermal; Tyramine pressor test

Indexed keywords

HYPERTENSIVE FACTOR; LABETALOL; SELEGILINE; TRANYLCYPROMINE; TYRAMINE;

ADULT; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG CAPSULE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FOOD DRUG INTERACTION; HEART PALPITATION; HUMAN; HYPERTENSION; MALE; MEAL; NAUSEA; NORMAL HUMAN; PRESSOR RESPONSE; SENSITIVITY ANALYSIS; TACHYCARDIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD-DRUG INTERACTIONS; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; REFERENCE VALUES; SELEGILINE; TIME FACTORS; TRANYLCYPROMINE; TYRAMINE;

EID: 33745928752     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006289852     Document Type: Article

References (49)

1. Strolin Benedetti M, Dostert P. Monoamine oxidase: from physiology and pathology to the design and clinical application of reversible inhibitors. Adv Drug Res. 1992;23:65-125.
2. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991;1:228-248.
3. Knoll J. The pharmacology of (-)deprenyl. J Neural Transm Suppl. 1986;22:75-89.
4. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology. 1978;57:33-38.
5. Pickar D, Cohen RM, Jimerson DC, Murphy DL. Tyramine infusions and selective monoamine oxidase inhibitor treatment: I. Changes in pressor sensitivity. Psychopharmacology. 1981;74:4-7.
6. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology. 1985;86:432-437.
7. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet. 1963;2:849-850.
8. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349-365.
9. Anderson MC, Hasan F, McCrodden JM, Tipton KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 1993;18:1145-1149.
10. Blackwell B, Marley E. Interactions of cheese and of its constituents with monoamine oxidase inhibitors. Br J Pharmacol. 1966;26:120-141.
11. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31-56.
12. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197-217.
13. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Gilman AG, Rall JW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon; 1990:187-220.
14. Hasan F, McCrodden JM, Kennedy NP, Tipton KF. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm. 1988;26:1-9.
15. Benedetti MS, Boncher T, Carlsson A, Fowler CJ. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1983;32:47-52.
16. Strolin Benedetti M, Dostert P. Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci. 1985;6:246-251.
17. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46:45-50.
18. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989;25:63-67.
19. Smiderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depression patients. Arch Gen Psychiatry. 1994;54:607-615.
20. Prasad A, Glover V, Goodwill BL, Sandler M, Signy M, Smith SE. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment. Psychopharmacology. 1988;95:540-543.
21. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27-34.
22. Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099-1104.
23. Bodkin JA, Amsterdam JD. Transdermal seligiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869-1875.
24. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208-214.
25. Ghose K. Tyramine pressor test: implications and limitations. Methods Find Exp Clin Pharmacol. 1984;6:455-464.
26. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol. 1991;11:55-59.
27. Davidson J, Raft D, Pelton S. An outpatient evaluation of phenelzine and imipramine. J Clin Psychiatry. 1987;48:143-146.
28. White K, Razani J, Cadow B, et al. Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial. Psychopharmacology. 1984;82:258-262.
29. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
30. Quitkin FM, Rothschild R, Stewart JW, McGrath PJ, Harrison WM. Atypical depression: unipolar depressive subtype with preferential response to MAOIs. In: Kennedy SH, ed. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington, DC: American Psychiatric Press; 1994:181-204.
31. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148:910-916.
32. Davidson JR, McLeod MN, Kurland AA, White HL. Antidepressant drug therapy in psychotic depression. Br J Psychiatry. 1977;131:493-496.
33. Amsterdam JD. Use of high dose tranylcypromine in resistant depression. In: Amsterdam JD, ed. Advances in Neuropsychiatry and Psychopharmacology: Vol. 2. Refractory Depression. New York: Raven; 1991:123-129.
34. Nolen WA, Hoencamp I, Haffmans PMJ, Bouvy PF. Classical and selective monoamine oxidase inhibitors in refractory major depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, eds. Refractory Depression: Current Strategies and Future Directions. New York: John Wiley; 1994:59-68.
35. Feiner AE, Waldmeier PC. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol. 1979;28:995-1002.
36. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther. 1965;155:154-164.
37. Schoepp D, Azzaro AJ. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem. 1981;36:2025-2031.
38. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl. 1989;28:21-31.
39. Korn A, Wagner B, Moritz E, Dingemanse J. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. Eur J Clin Pharmacol. 1996;49:273-278.
40. Mendis N, Pare CM, Sandler M, Glover V, Stern GM. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology. 1981;73:87-90.
41. Simpson G, White K, Pi E, Razani J, Sloane B. Monoamine oxidase inhibition and tyramine sensitivity in L-deprenyl-treated subjects. Psychopharmacol Bull. 1983;19:340-342.
42. Stern GM, Lees AJ, Sandler M. Recent observations on the clinical pharmacology of (-)deprenyl. J Neural Transm. 1978;43:245-251.
43. Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 1996;3:688-698.
44. Ziemniak JA, Kemper EM, Goodhead M, Azzaro AJ. Pharmacokinetics of selegiline administered via transdermal patch, single oral dose, or intravenous infusion. Presented at: the New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; May 29, 2001; Phoenix, Ariz.
45. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9:397-402.
46. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclohemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989;46:344-351.
47. Ekstedt B, Magyar K, Knoll J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem Pharmacol. 1979;28:919-923.
48. VanDenBerg C, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003;43:604-609.
49. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm Suppl. 1988;26:57-71.